BioLineRx inks licensing deal, share purchase agreement

seekingalpha

21 Nov 2024

Daniel Grizelj

BioLineRx (NASDAQ:BLRX) ARDs fell ~19% in the premarket Thursday after the Israeli biotech announced a share purchase agreement in conjunction with a licensing deal with U.K.-based Ayrmid for its lead asset motixafortide, marketed in the U.S. as Aphexda.

According to the deal terms, Ayrmid, the parent company of cell therapy developer Gamida Cell (OTC:GMDAQ), is set to receive an exclusive license to develop and commercialize Aphexda across all indications except cancer.

In return, Hevel Modi'in-based BioLineRx (NASDAQ:BLRX) will receive $10M upfront payments and is eligible to receive up to an additional $87M in commercial milestones plus 18%–23% royalties on net sales.

The licensing deal will take effect worldwide except in Asia, where BioLineRx (BLRX) has granted an exclusive license for Aphexda to Chinese biotech Gloria Biosciences.

Concurrently, the company said it entered into a share purchase agreement with certain funds managed by Highbridge Capital Management, LLC to raise as much as $9M as part of an equity investment expected to close on Thursday.

The deals with Ayrmid and Gloria, along with equity investment from Highbridge Capital, “are expected to provide a strong foundation for BioLineRx to advance its pipeline and identify potential additional assets for development,” the company added.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2485496506"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2485496506\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2485496506?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1126636461/image_1126636461.jpg?io=getty-c-w750","is_english":true,"pubTime":"2024-11-21 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2485496506","market":"fut","top_or_hot":-1,"title":"BioLineRx inks licensing deal, share purchase agreement","media":"seekingalpha","content":"<html><body><figure><picture><img height=\"5304px\" sizes=\"(max-width: 768px) calc(100vw - 36px), (max-width: 1024px) calc(100vw - 132px), (max-width: 1200px) calc(66.6vw - 72px), 600px\" src=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1126636461/image_1126636461.jpg?io=getty-c-w750\" srcset=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1126636461/image_1126636461.jpg?io=getty-c-w1536 1536w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1126636461/image_1126636461.jpg?io=getty-c-w1280 1280w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1126636461/image_1126636461.jpg?io=getty-c-w1080 1080w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1126636461/image_1126636461.jpg?io=getty-c-w750 750w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1126636461/image_1126636461.jpg?io=getty-c-w640 640w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1126636461/image_1126636461.jpg?io=getty-c-w480 480w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1126636461/image_1126636461.jpg?io=getty-c-w320 320w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1126636461/image_1126636461.jpg?io=getty-c-w240 240w\" width=\"7952px\"/></picture><figcaption><p>Daniel Grizelj</p></figcaption></figure><p>BioLineRx (<span>NASDAQ:BLRX</span>) ARDs <span>fell ~19%</span> in the premarket Thursday after the Israeli biotech announced a share purchase agreement in conjunction with a licensing deal with U.K.-based Ayrmid for its lead asset motixafortide, marketed in the U.S. as Aphexda.</p> <p>According to<span> the deal terms, Ayrmid, the parent company of cell therapy developer Gamida Cell (</span>OTC:GMDAQ<span>), is set to receive an exclusive license to develop and commercialize Aphexda across all indications except cancer.</span></p> <p>In return, Hevel Modi'in-based BioLineRx (<span>NASDAQ:BLRX</span>) will receive $10M upfront payments and is eligible to receive up to an additional $87M in commercial milestones plus 18%–23% royalties on net sales.</p> <p>The licensing deal will take effect worldwide except in Asia, where BioLineRx (BLRX) has granted an exclusive license for Aphexda to Chinese biotech Gloria Biosciences.</p> <p>Concurrently, the company said it entered into a share purchase agreement with certain funds managed by Highbridge Capital Management, LLC to raise as much as $9M as part of an equity investment expected to close on Thursday.</p> <div></div><p>The deals with Ayrmid and Gloria, along with equity investment from Highbridge Capital, “are expected to provide a strong foundation for BioLineRx to advance its pipeline and identify potential additional assets for development,” the company added.</p> </body></html>","source":"seekingalpha_trending_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioLineRx inks licensing deal, share purchase agreement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioLineRx inks licensing deal, share purchase agreement\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-21 21:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4316271-biolinerx-stock-sinks-share-purchase-deal><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Daniel GrizeljBioLineRx (NASDAQ:BLRX) ARDs fell ~19% in the premarket Thursday after the Israeli biotech announced a share purchase agreement in conjunction with a licensing deal with U.K.-based ...</p>\n\n<a href=\"https://seekingalpha.com/news/4316271-biolinerx-stock-sinks-share-purchase-deal\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://seekingalpha.com/news/4316271-biolinerx-stock-sinks-share-purchase-deal","article_id":"2485496506","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1126636461/image_1126636461.jpg?io=getty-c-w750"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2485496506","pubTimestamp":1732194010,"columns":[],"sourceInfo":{"source_id":"seekingalpha_trending_news","name":"Seeking Alpha Trending News"},"weMediaInfo":null,"summary":"Daniel GrizeljBioLineRx (NASDAQ:BLRX) ARDs fell ~19% in the premarket Thursday after the Israeli biotech announced a share purchase agreement in conjunction with a licensing deal with U.K.-based Ayrmi","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"BioLineRx签署许可协议、股份购买协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{".IXIC":0.61,"BLRX":0.9,"MNQmain":0.6,"NQmain":0.6,"GMDAQ":0.9,"PSQ":0.6,"QID":0.6,"QLD":0.6,"SQQQ":0.6,"TQQQ":0.6},"content_text":"Daniel GrizeljBioLineRx (NASDAQ:BLRX) ARDs fell ~19% in the premarket Thursday after the Israeli biotech announced a share purchase agreement in conjunction with a licensing deal with U.K.-based Ayrmid for its lead asset motixafortide, marketed in the U.S. as Aphexda. According to the deal terms, Ayrmid, the parent company of cell therapy developer Gamida Cell (OTC:GMDAQ), is set to receive an exclusive license to develop and commercialize Aphexda across all indications except cancer. In return, Hevel Modi'in-based BioLineRx (NASDAQ:BLRX) will receive $10M upfront payments and is eligible to receive up to an additional $87M in commercial milestones plus 18%–23% royalties on net sales. The licensing deal will take effect worldwide except in Asia, where BioLineRx (BLRX) has granted an exclusive license for Aphexda to Chinese biotech Gloria Biosciences. Concurrently, the company said it entered into a share purchase agreement with certain funds managed by Highbridge Capital Management, LLC to raise as much as $9M as part of an equity investment expected to close on Thursday. The deals with Ayrmid and Gloria, along with equity investment from Highbridge Capital, “are expected to provide a strong foundation for BioLineRx to advance its pipeline and identify potential additional assets for development,” the company added.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}